PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 9/16, 9/02, 9/00, 9/48

A1

(11) International Publication Number: WO 98/56356

(43) International Publication Date: 17 December 1998 (17.12.98)

(21) International Application Number: PCT/GB98/01673

(22) International Filing Date: 8 June 1998 (08.06.98)

(30) Priority Data:
9711962.2 10 June 1997 (10.06.97) GB

(71) Applicant *(for all designated States except US)*: RECKITT & COLMAN PRODUCTS LIMITED [GB/GB]; One Burlington Lane, London W4 2RW (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: STATHAM, Fiona, Kate [GB/GB]; Autherd Cottage, 38 East End, Walkington, Beverley HU17 8RY (GB).

(74) Agents: DALE, Martin, Nicholas et al.; Reckitt & Colman plc, Group Patents Dept., Dansom Lane, Hull HU8 7DS (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPEUTICALLY ACTIVE COMPOSITIONS

(57) Abstract

A pharmaceutical composition for the treatment of irritable bowel syndrome which composition includes a carrier vehicle and a vanilloid compound is provided. The carrier vehicle enables the vanilloid compound to be released in the lower GI tract. The vanilloid compound has the effect of desensitising nerves in the lower GI tract leading to the relief of symptoms of irritable bowel syndrome.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

THERAPEUTICALLY ACTIVE COMPOSITIONS

The present invention relates to compositions for the treatment of irritable bowel syndrome (IBS) and more particularly to locally acting compositions which are active in the post-stomach region of the gastro-intestinal (GI) tract.

Irritable Bowel Syndrome (IBS) is part of a spectrum of diseases known generally as Functional Gastrointestinal Disorders which include diseases such as non-cardiac chest pain, non-ulcer dyspepsia, and chronic constipation or diarrhoea. These diseases are all characterised by chronic or recurrent gastrointestinal symptoms for which no structural or biochemical cause can be found. Irritable bowel syndrome in the UK alone is responsible for 30-50% of all gastroenterology referrals to secondary care.

IBS is believed to be due to a number of factors such as physiological, emotional, cognitive and behavioural factors and is frequently encountered during periods of stress. Diagnosis of IBS is one of exclusion and is based on the observed symptoms in any given case. Commonly accepted criteria for IBS, known as the "Rome" criteria, include at least 3 months of continuous or recurrent symptoms of:

1. abdominal pain or discomfort that is relieved with defecation, and/or associated with a change in the frequency of stools, and/or associated with a change in the consistency of stool; and
2. two or more of the following on at least a quarter of occasions: altered stool frequency,

altered stool form, altered stool passage, passage of mucus, and/or bloating or feeling of abdominal distension.

Conventional treatments of IBS are based on the severity and the nature of each person's symptoms and whether or not any psychological factors are involved. Treatment of IBS may include one or more of the following: lifestyle changes, pharmacological treatment and psychological treatment. However, there is no general treatment which is applicable to all cases of IBS.

In certain cases, the exclusion of foods which aggravate IBS symptoms is recommended. However, this type of treatment is only effective when the underlying cause of IBS is related to diet.

Pharmacologically active agents are often used to treat IBS. Anti-diarrhoeals (for example, loperamide), smooth muscle relaxants (for example, mebeverine hydrochloride or alverine citrate), or antidepressants may be effective in treating IBS. However, there is no single pharmacologically active agent which is completely effective in alleviating the symptoms or curing IBS.

Psychological factors may be used in the treatment of IBS. Again, however, this treatment does not provide a universal cure for the symptoms of IBS since not all cases of IBS are due to psychological factors.

One method of treating pathological conditions of the small and large intestines is disclosed in US Patent No. 5431914. This patent discloses that the external application of capsaicin to the skin in specific regions affects certain nerves in the skin which lead to spinal cord segments. Thus, it is suggested that topical application of a dose of 0.03mg capsaicin to the anterior and posterior divisions of spinal nerves T12 to S3 can be used to treat IBS. However, a clear mechanism of the mode of operation of this invention is not known.

Such a regime of self-administration is unlikely to be effective because the composition must be applied to a specific site which is not necessarily readily apparent to the patient. In addition, it is likely to be difficult to control the dosage when applying the composition of US Patent No. 5431914 since it is in the form of a topical cream.

A need therefore exists for a composition which is able to relieve the symptoms of irritable bowel syndrome which ideally is in a form which is easily handled, may be administered in a unit dosage form and which is capable of being self administered by patients.

To alleviate the problems of IBS, according to a first aspect to the present invention, there is provided a pharmaceutical composition for use in the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal,

preferably a human patient, the composition comprising:

i) one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and/or derivatives thereof, (component a); and

ii) a pharmaceutically acceptable vehicle (component b),

wherein component b) is selected to enable component a) to be released in the gastrointestinal tract between the stomach and the rectum of the mammal.

Preferably component a) is present in a IBS symptom alleviating amount.

Preferably the composition according to the invention contains from 0.001 to 30% of component a), more preferably from 0.01 to 20%, most preferably from 0.1 to 10% by weight of the pharmaceutical composition.

Preferably the composition according to the invention contains from 70 to 99.999% component b), more preferably from 80 to 99.99%, most preferably from 90 to 99.9% by weight of the composition.

According to a second aspect of the invention, there is provided a pharmaceutical composition as described above with respect to the first aspect of the invention, but which further includes an enteric coating (component c) encasing components (a) and (b).

According to a third aspect of the invention, there is provided a process for the alleviation of symptoms associated with Irritable Bowel Syndrome (IBS) in a mammalian patient, preferably a human patient, afflicted with said symptoms, which process comprises the step of:

administering, preferably orally administrating, a therapeutically effective amount of the pharmaceutical composition according to either the first, or second aspects of the invention as described above, in order to alleviate said symptoms associated with Irritable Bowel Syndrome (IBS).

According to a fourth aspect of the invention, there is provided the process according to the third aspect of the invention as described above, wherein the pharmaceutical composition is in a sustained release form, which form is substantially released (i.e., at least 75% of component (a) in the pharmaceutical composition) in the gastrointestinal region after the stomach and before the rectum of the patient being treated.

In the context of the present invention, component a) should be understood to be a compound or a mixture of compounds having a biologically active vanillyl group. Component a) therefore includes both naturally occurring and synthetic vanilloids, pharmaceutically acceptable salts of the vanilloid compound (whether natural or synthetic) as well as pharmaceutically acceptable

derivatives and/or analogues thereof (whether natural or synthetic).

Included in the ambit of the naturally occurring vanilloid compounds are both crude extracts and purified extracts of active vanilloid compounds.

Examples of natural vanilloid compounds suitable for use in the present invention therefore include both the crude extracts and the purified extracts of active vanilloid compounds from: capsicum, cayenne pepper, black pepper, paprika, cinnamon, clove, mace, mustard, ginger, tumeric, papaya seed and the cactus-like plant *Euphorbia resinifera*.

Synthetic vanilloid compounds such as synthetic capsaicin as defined in WO 96/40079 are also envisaged to be included in or comprise component a) in the compositions of the present invention and the disclosure of such compounds as exemplified in WO 96/40079 is incorporated herein by reference.

The composition of the present invention may therefore include both a crude vanilloid compound-containing extract (obtained by extracting the natural product) and/or a pure vanilloid compound itself (obtained either by synthesis or by refining a crude extract). Thus, in the case of capsaicin, for example, one might also find dihydrocapsaicin present in the crude extract.

In so far as the pharmaceutically acceptable salts of component a) are concerned, the therapeutic activity resides in the moiety derived from the vanilloid, and identity of any salt portion when present is of minor importance.

For therapeutic and prophylactic purposes, examples of pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic acids.

In a preferred embodiment of the present invention active vanilloid compounds of component a) are selected from capsaicin ((E)-(N)-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide); eugenol (2-methoxy-4-(2-propenyl)phenol); zingerone (4-(4-hydroxy-3-methoxyphenyl)-2-butanone); curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); piperine (1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl] piperidine); resiniferatoxin (6,7-deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-20-(4-hydroxy-3-methoxybenzeneacetate)) or pharmaceutically effective salts, analogues, derivatives or equivalents thereof. Capsaicin, eugenol and resiniferatoxin are more preferred with capsaicin being most preferred.

Component b) of the present invention may comprise and/or include one or more pharmaceutically acceptable excipients or diluents. Such excipients or diluents include but are not limited to mixtures of polyalcohol glycerol and fatty acid esters such as Gelucire (TM of Gattefosse), a carbomer such as Carbopol 947P (TM of Goodrich), calcium carbonate, microcrystalline cellulose, sodium bicarbonate, lactose, croscarmellose sodium, magnesium stearate, talc, dioctyl sodium sulphosuccinate, hydroxypropylmethyl cellulose, methyl paraben, tris (hydroxymethyl)methylamine, citric acid monohydrate, cocoa butter, gelatin, glycerin and/or hydrogenated vegetable oils.

Preferably the composition is an oral delivery form. A composition according to one embodiment of the present invention is therefore preferably administered orally in a sustained-release form to release component a) in the lower GI tract to induce desensitisation, thereby protecting the patient from pain or discomfort associated with the lower GI tract.

The composition may be provided in unit dosage form as a tablet, a capsule, a gel, a powder, spheroids and/or granules. In an especially advantageous embodiment, the composition is provided as a tablet, capsule, spheroid or granule provided with an enteric coating.

Preferably, the excipients and/or diluents are present in an amount of from 0.1mg to 1500mg,

most preferably from 10mg to 100mg per unit dosage form.

Preferably a tablet unit dosage form comprises:

i) 0.01 to 300mg of component a);

ii) any one or more of

0.1 to 500mg microcrystalline cellulose;

0.1 to 200mg lactose or equivalent sugar;

0.1 to 90mg croscarmellose salt, preferably croscarmellose sodium;

0.1 to 20mg of a stearate salt, preferably magnesium stearate; and

iii) an enteric coating of from 1 to 500μm,

all weights being per 1000mg of composition.

Preferably a capsule unit dosage form comprises:

i) 0.01 to 300mg component a);

ii) any one or more of

0.1 to 250mg mixture of polyalcohol glycerol and fatty acid esters;

0.1 to 500mg microcrystalline cellulose;

0.1 to 200mg lactose or equivalent sugar;

0.1 to 90mg croscarmellose salt, preferably croscarmellose sodium;

0.1 to 20mg talc;

0.1 to 20mg of a stearate salt, preferably magnesium stearate; and

iii) an enteric coating of from 1 to 500μm,

all weights being per 1000mg of composition.

Preferably a gel unit dosage form comprises:

i) 0.01 to 300mg component a);

ii) at least 0.1 to 999.99mg of a pharmaceutically acceptable polymer gel; and
iii) water, preferably deionised water,
all weights being per 1000mg of composition.

Preferably a powder unit dosage form comprises:
i) 0.01 to 300mg component a); and
ii) any one or more of
0.1 to 200mg of a carbonate, preferably calcium carbonate;
0.1 to 500mg microcrystalline cellulose; and
0.1 to 50mg of a bicarbonate, preferably sodium bicarbonate,
all weights being per 1000mg of composition.

Preferably a spheroid unit dosage form comprises:
i) 0.01 to 300mg component a); and
ii) any one or more of
0.1 to 500mg microcrystalline cellulose;
0.1 to 200mg lactose or equivalent sugar;
0.1 to 90mg a croscarmellose salt, preferably croscarmellose sodium; and
iii) an enteric coating of from 1 to 500µm,
all weights being per 1000mg of composition.

Preferably a granule unit dosage form comprises:
i) 0.01 to 300mg component a); and
ii) any one or more of
0.1 to 200mg carbopol;
0.1 to 200mg of a carbonate, preferably calcium carbonate;
0.1 to 500mg microcrystalline cellulose; and

0.1 to 50mg of a bicarbonate, preferably sodium bicarbonate,
all weights being per 1000mg of composition.

The capsules or spheroids may be liquid- or solid-filled. The important feature is that the mode of delivery enables release, preferably sustained release, of component a) in the lower GI tract. Other suitable delivery forms such as matrix tablets and wax matrices will therefore be apparent to the skilled person.

Preferably, each unit dosage contains from 0.01 to 300mg, preferably 0.1 to 25mg, most preferably 1 to 20mg of component a) per 1000mg of composition.

The amount of component a) required will depend on the particular vanilloid compound used, the severity of the condition being treated, the nature of the oral composition, and the age, weight and condition of the patient.

The dosage administered may ultimately be at the discretion of an attendant physician or may be within a pre-defined range for self-administration by the patient. However, an effective amount of component a) for the treatment of IBS will generally be in the range of 0.01mg to 40mg per day and more usually will be in the range of 0.1mg to 10mg per day. This amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is as noted previously.

The amount of component a) contained in the composition will, of course, depend on component b) as well as on the particular vanilloid compound(s) included in component a). For example, capsaicin is much more effective than eugenol and thus the dosage of capsaicin which is needed to achieve the same effect as a dosage of another vanilloid compound, such as eugenol, may be 10 or 100 times smaller.

An effective amount of component a) in the case in which the vanilloid compound is present as a salt may be determined as a proportion of the effective amount of the free active vanilloid compound per se.

As mentioned previously the composition may be enterically coated to provide release of component a) in the gastrointestinal tract between the stomach and the rectum. The enteric coating applied to the unit dosage form may range in thickness form between 1 and 500μm, preferably between 5 and 100μm, most preferably between 20 and 50μm.

A suitable enteric coating comprises pH sensitive biodegradable polymers, as, for example, included in Opadry Aqueous Enteric, manufactured by Colorcon.

It will be appreciated, however, that other release mechanisms for post stomach (enteric) delivery of component a) may be used, for example, non-pH sensitive biodegradable polymers, or other

materials useful for enteric delivery as known in the art.

Alternatively, or in conjunction with the above, the composition may be rectally delivered to the mammal, for example by way of an enema formulation or a suppository.

Preferably an enema formulation contains:
i) 0.01 to 300 percentage weight per volume (%w/v) component a); and
ii) any one or more of
0.01 to 10%w/v Dioctyl sulphosuccinate salt, preferably Dioctyl sodium sulphosuccinate;
0.01 to 10%w/v Hydroxypropylmethylcellulose(HPMC);
0.001 to 10%w/v Methyl paraben;
0.001 to 10%w/v Tris(hydroxymethyl)methylamine;
0.001 to 10%w/v Citric acid monohydrate; and
iii) the balance being water, preferably deionised water.

Preferably a suppository contains:
i) 0.01 to 300mg component a); and
ii) any one or more of
0.1 to 999.99mg cocoa butter, gelatin, glycerin and/or hydrogenated vegetable oils; and
iii) the balance being water, preferably deionised water
all weights being per 1000mg composition.

According to a further aspect to the present invention, there is provided the use of one or more vanilloid compounds, pharmaceutically

acceptable salts, analogues and/or derivatives thereof in the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal, said use comprising releasing a therapeutically effective amount of the vanilloid compound(s), pharmaceutically acceptable salts, analogues and/or derivatives thereof in the gastrointestinal tract between the stomach and the rectum of the mammal.

According to a further aspect to the present invention, there is provided the use of one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and/or derivatives thereof for the manufacture of a medicament for the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal, wherein the one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and/or derivatives thereof are released in the gastrointestinal tract between the stomach and the rectum of the mammal.

A further aspect to the present invention provides a method of treating the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal, the method comprising administering to a mammal in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising

i) one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and/or derivatives thereof (component a); and

ii) a pharmaceutically acceptable vehicle (component b),

wherein component b) is selected to enable component a) to be released in the gastrointestinal tract between the stomach and the rectum of the mammal.

A further aspect to the present invention provides a process for the manufacture of a composition according to the invention, the process including the steps of mixing component a) with component b).

It will be appreciated that the compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association component a) with component b), and excipient(s) and/or diluents when present.

Each of the materials described in this specification are commercially available from various sources.

The following examples illustrate compositions according to the invention.

Example 1 - Hard gelatin capsule

The capsule contains:

Capsaicin	10 mg
Gelucire (TM of Gattefosse) 53/10	90 mg

The ingredients are melted by heating to around 65°-75°C and the capsule is filled with a 100mg amount of the melt, which is then allowed to solidify. The capsules are coated with an enteric coating to provide release in the intestine. Gelucire (TM of Gattefosse) consists of mixtures of polyalcohol glycerol and fatty acid esters and the capsaicin is thus dispersed in this lipophilic material.

Example 2 - Bioadhesive granule

Each capsule contains 10mg of capsaicin in granular form. The granules are formed of the following ingredients (the weight given for each ingredient being that required to provide sufficient granules to achieve the desired dosage per capsule):

Capsaicin	10 mg
Carbopol 947P (TM of Goodrich)	80 mg
Calcium carbonate	80 mg
Microcrystalline cellulose	200mg
Sodium bicarbonate	15 mg

The carbopol, calcium carbonate and microcrystalline cellulose in the form of dry powders are mixed in a high speed food processor. The capsaicin is dissolved in isopropanol and mixed with the resulting powder mixture. The solvent is then dried off at 20°C, sodium

bicarbonate is added in powder form and mixed with the dry mass. The resulting mixture is granulated with water and dried at 40°C in a fluid bed drier to a moisture content of less than 5%w/w. The granules are filled into size one hard gelatin capsules which are then coated with enteric coating polymer.

Example 3 - Enteric-coated Tablet

Capsaicin	10mg
Microcrystalline Cellulose	172mg
Lactose	85mg
Croscarmellose Sodium	30mg
Magnesium Stearate	3mg

The ingredients are blended and compressed directly into tablets. The tablets are coated with an enteric coating to ensure that capsaicin is released after passing through the stomach. An example of such an enteric coating is Opadry Aqueous Enteric (manufactured by Colorcon).

Example 4 - Hard Gelatin Capsule

Capsaicin	10mg
Microcrystalline Cellulose	170mg
Lactose	85.5mg
Croscarmellose Sodium	30mg
Talc	3mg
Magnesium Stearate	1.5mg

The ingredients are blended and filled into hard gelatin capsules (for example, size 2). The capsules are then coated with an enteric coating, for example with Opadry Aqueous Enteric.

Example 5 - Extrusion Spheronised Pellets in a Hard Gelatin Capsule

Capsaicin	10mg
Microcrystalline Cellulose	130mg
Lactose	130mg
Croscarmellose Sodium	15mg

The powders are blended together and then wet massed in a high-shear mixer/granulator. The mass is extruded through a screen (for example, 1mm) and then spheronised. The spheroids are dried in a fluid-bed dryer and then coated with an enteric coat, for example Opadry Aqueous Enteric. The coated spheroids are filled into hard gelatin capsules (for example, size 2).

Example 6 - Hard gelatin capsule

The capsule contains:

Resiniferatoxin	10 mg
Gelucire (TM of Gattefosse) 53/10	90 mg

The ingredients are melted by heating to around 65°-75°C and the capsule is filled with a 100mg of the melt, which is then allowed to solidify. The capsules are coated with an enteric coating to provide release in the intestine. Gelucire (TM of Gattefosse) consists of mixtures of polyalcohol glycerol and fatty acid esters and the capsaicin is thus dispersed in this lipophilic material.

Example 7 - Foam enema

The enema formulation contains:

Ingredient		%wt/v
Eugenol		0.15
Dioctyl sodium sulphosuccinate		1.0
Hydroxypropylmethylcellulose(HPMC)		1.3
Methyl paraben		0.15
Tris(hydroxymethyl)methylamine		0.15
Citric acid monohydrate		0.08
Deionised water	to	100ml

The citric acid, tris and methyl paraben are dissolved in 50ml of deionised water and stirred. HPMC is added to this solution to give solution A. Dioctyl sodium sulphosuccinate is dissolved separately in 25ml deionised water and the eugenol added to the solution to give solution B. Solutions A and B are carefully mixed to avoid foaming and made to up to 100ml with deionised water.

Example 8 - Suppository

Each suppository contains:

Capsaicin	10 mg
Gelatin	200 mg
Glycerin	700 mg
Deionised water:	90 mg

The amounts illustrated above are understood to be per suppository and should therefore be multiplied by the number of suppositories it is expected each production batch will yield.

The ingredients are mixed together and melted at between 60° and 70°C. The melted mass is poured into disposable moulds of plastic material in which the suppositories are cast and remain enclosed until removed by the patient.

Example 9 - Treatment of IBS in a human patient

A human patient suffering from one or more of the following symptoms: diarrhoea, constipation, abdominal pain, abdominal bloating, abdominal distention, altered stool frequency, altered stool form, altered stool passage or passage of mucus (symptoms associated with Irritable Bowel Syndrome (IBS) is administered a therapeutically effective amount of the pharmaceutical composition according to any of Examples 1 to 8 by either oral or rectal administration, wherein the pharmaceutical composition is administered with sufficient frequency (one administration of the pharmaceutical composition, or multiple administrations of the pharmaceutical composition) in order to alleviate one or more of the symptoms in the said patient.

CLAIMS:

1. A pharmaceutical composition for use in the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal, the composition comprising:
i) one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and/or derivatives thereof (component a); and
ii) a pharmaceutically acceptable vehicle (component b),
wherein component b) is selected to enable component a) to be released in the gastrointestinal tract between the stomach and the rectum of the mammal.

2. A composition as claimed in claim 1 wherein the composition is an oral delivery composition and the component b) releases component a) only after the composition has passed through the stomach.

3. A composition as claimed in either one of claims 1 and 2 wherein component a) is selected from capsaicin ((E)-(N)-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide); eugenol (2-methoxy-4-(2-propenyl)phenol); zingerone (4-(4-hydroxy-3-methoxyphenyl)-2-butanone); curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); piperine (1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl] piperidine); resiniferatoxin (6,7-deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-20-(4-hydroxy-3-methoxybenzeneaceta

te)) or pharmaceutically effective salts, analogues or derivatives or extracts or synthetic equivalents thereof.

4. A composition as claimed in any one of the previous claims in unit dosage form as a tablet, a capsule, a gel, a powder, spheroids, granules or an osmotic delivery device.

5. A composition as claimed in claim 4 wherein the unit dosage contains from 0.01 to 300mg, preferably 0.1 to 20mg of component a).

6. A composition as claimed in any one of claims 2 to 5 wherein composition is enterically coated to provide release of component a) in the gastrointestinal tract between the stomach and the rectum of a mammal.

7. Use of one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and derivatives thereof in the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal, said use comprising releasing a therapeutically effective amount of the vanilloid compound(s) in the gastrointestinal tract between the stomach and the rectum of the mammal.

8. Use of one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and derivatives thereof for the manufacture of a medicament for the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a

mammal, wherein the vanilloid compound(s) are released in the gastrointestinal tract between the stomach and the rectum of the mammal.

9. A method of treating the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension in a mammal, the method comprising administering to a mammal in need thereof, a pharmaceutically effective amount of a pharmaceutical composition comprising

i) one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and/or derivatives thereof; and

ii) a pharmaceutically acceptable vehicle, wherein the vehicle is selected to enable the vanilloid compound(s) to be released in the gastrointestinal tract between the stomach and the rectum of the mammal.

10. A process for the manufacture of a composition as claimed in any one of claims 1 to 5, the process including the steps of mixing one or more vanilloid compounds, pharmaceutically acceptable salts, analogues and derivatives thereof with a pharmaceutically acceptable vehicle.

INTERNATIONAL SEARCH REPORT

Interna al Application No
PCT/GB 98/01673

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/16 A61K9/02 A61K9/00 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	EP 0 015 334 A (J. B. TILLOTT) 17 September 1980 see claims 1,5,6,8 see page 1, line 1 - line 16 see page 4, line 7 - line 23 see page 5, line 3 - line 7 see page 5, line 21 - line 25 see page 6, line 14 - line 22 ---	1-10 1-10
X	DE 41 37 540 A (STEIGERWALD ARZNEIMITTELWERK) 19 May 1993 see claims 1-4,7 see page 9; example 6 ---	1,3-5, 7-10
X	US 5 063 060 A (JOEL E. BERNSTEIN) 5 November 1991 see claims 1,4,5 see column 2, line 62 - line 68 --- -/--	1,3-5, 7-10

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 October 1998	24.09.98

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Ventura Amat, A

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Interna[illegible]al Application No
PCT/GB 98/01673

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 03674 A (SABINSA CORPORATION) 6 February 1997 see claims 1,2 see page 18, line 8 - line 17 see page 19, line 1 - line 9 ---	3
Y	WO 93 23061 A (STAGGS, JEFF) 25 November 1993 see claims 1,70,142,146,160 ---	3
Y	FR 2 207 705 A (MARCONNET, RENE) 21 June 1974 see claims 1-4,6 see page 3, line 39 - page 4, line 28 -----	1-10

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern ial Application No
PCT/GB 98/01673

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 15334	A	17-09-1980	AU	525895 B	09-12-1982
			AU	4511479 A	18-09-1980
			GB	2006011 A,B	02-05-1979
			HK	73983 A	06-01-1984
			KE	3296 A	17-02-1984
			US	4687667 A	18-08-1987
DE 4137540	A	19-05-1993	US	5401777 A	28-03-1995
			CA	2082562 A	15-05-1993
			EG	20056 A	27-03-1997
			EP	0550807 A	14-07-1993
			JP	5262659 A	12-10-1993
			PL	296570 A	02-11-1993
			SK	337492 A	10-05-1995
			ZA	9208554 A	05-05-1993
US 5063060	A	05-11-1991	AT	138567 T	15-06-1996
			AU	645023 B	06-01-1994
			AU	6064890 A	18-07-1991
			CA	2070685 A,C	20-06-1991
			DE	69027220 D	04-07-1996
			DE	69027220 T	02-01-1997
			DK	506658 T	24-06-1996
			EP	0506658 A	07-10-1992
			ES	2087160 T	16-07-1996
			IL	95820 A	04-08-1996
			JP	7080761 B	30-08-1995
			JP	5504546 T	15-07-1993
			KR	9515056 B	21-12-1995
			RU	2095060 C	10-11-1997
			WO	9108738 A	27-06-1991
WO 9703674	A	06-02-1997	AU	6455596 A	18-02-1997
			EP	0839037 A	06-05-1998
WO 9323061	A	25-11-1993	AU	4382693 A	13-12-1993
			DE	4392300 T	07-12-1995
			GB	2286120 A,B	09-08-1995
FR 2207705	A	21-06-1974	NONE		